VI Autologous Bone Marrow Transplantation.pdf - Blog Science ...

More documents

Recommendations

Info

Table 1. Combination Chemotherapy Regimen VP-16/Platinol in NSCLC VP-16 200 mg/m 2 Platinol 30 mg/m 2 Day 1 2 3 4 5 6-16 + + + + + + Neupogen +-+ Cycle q 3 weeks Step 1: Cytoxan 2 gm/m 2 Platinol 90 mg/m 2 Step 2: Cytoxan 2 gm/m 2 VP-16 600 mg/m 2 Step 3: Cytoxan 4-5 gm/m 2 VP-16 750 mg/m 2 Platinol 90 mg/m 2 Table 2. Intensification Program in NSCLC Table 3. NSCLC Patient Characteristics Age 64 (49-72) Male/Female 5/6 pts. COPD 3/11 pts. Smokers 11/11 pts. Adeno Ca Large cell Ca Squamous cell Ca Stage III Stage IV 5 pts. 4 pts. 2pts. 3 pts. 8 pts. Support G-CSF G-CSF BMT G-CSF GM-CSF 276 SIXTH INTERNATIONAL SYMPOSIUM ON AUTOLOGOUS BONE MARROW TRANSPLANTATION
Table 4. Resulte of VP-16/Platlnol Program in NSCLC Number of patients: 11 Duration response: *7+ (5+-13+) Duration survival: *7+ (4-13+) Alive: 8 Dead: 3 Response Rate: 72% (8 out of 11) *Median Table 5. Hematological Data of the VP-16/Platinol Regimen in NSCLC (1) White Blood Cells Course Onset X10 3 Nadir Peak Count Day X10 3 Count Day 1 6(5-10) 1.5(1.5-2.9) 12 12 15 2 9(5-27) 3.1(2.6-6.8) 11 53 15 3 10(5-25) 4.6(2.2-6.9) 11 48 15 4 14(4-20) 2.7(0.9-3.4) 13 50 16 5 5(4-13) 2.0(1-3.1) 10 51 16 6 12(5-52) 1.6(1.0-5.2) 12 54 16 SIXTH INTERNATIONAL SYMPOSIUM ON AUTOLOGOUS BONE MARROW TRANSPLANTATION 177
Page 1:
Autologous Bone Marrow Transplantat
Page 5 and 6:
CONTENTS nviAum TMLHTA'I OTT! 7 A l
Page 7 and 8:
AUTOLOGOUS BONE MARROW TRANSPLANTAT
Page 9 and 10:
TREATMENT OF NONSMALL CELL LUNG CAN
Page 11:
SUMMARY OF THE NON HODGKIN LYMPHOMA
Page 15:
Session I: Leukemia
Page 18 and 19:
TRIAL PROGRESS The trial opened in
Page 20 and 21:
Table 1. Achievement of Second Remi
Page 22 and 23:
ALLOGENEIC VERSUS AUTOLOGOUS BONE M
Page 24 and 25:
pts). The other 56 pts are too earl
Page 26 and 27:
Figure 1 EORTC-GIMEMA AML 8 A EORTC
Page 28 and 29:
PATIENTS AND METHODS Patients The B
Page 30 and 31:
Thus, as the results of some ongoin
Page 32 and 33:
COMPARISON OF INTENSIVE CONSOLIDATI
Page 34 and 35:
over, 13 pts who had received ICC1
Page 37:
Session II: Future Directions
Page 40 and 41:
in a previous report 3 . Analysis a
Page 42 and 43:
Engraftment of granulocyte, monocyt
Page 44 and 45:
0.2 - 0.1 - ABMT with mAb purging f
Page 46 and 47:
ENHANCED REGENERATION OF NATURAL KI
Page 48 and 49:
RESULTS The in vivo immune effects
Page 50 and 51:
16. Rizzoli V, Mangoni L, Carlo-Ste
Page 52 and 53:
hydroperoxycyclophosphamide (4HC)-t
Page 54 and 55:
survival in patients undergoing ABM
Page 56 and 57:
IMMUNOTHERAPY OF AML AFTER ABMT - S
Page 58 and 59:
Otherwise toxicity was mild to mode
Page 60 and 61:
Therapy. Amsterdam Elsevier 1987;89
Page 62 and 63:
200 IL6 in serum 44 SIXTH INTERNATI
Page 64 and 65:
sodes), fewer days of i.v. antibiot
Page 67:
Session III: Myeloma
Page 70 and 71:
trary, in case of adequate collecti
Page 72 and 73:
tion is considered, and all the mor
Page 74 and 75:
Table 3: Cost effectiveness of high
Page 77:
Session W: Lymphoma
Page 80 and 81:
METHODS Selection of patients and t
Page 82 and 83:
marrow treatment. Am J Med 85:829,1
Page 84 and 85:
HIGH DOSE THERAPY WITH HEMATOPOIETI
Page 86 and 87:
in TC 19 medium (Flobio), with an h
Page 88 and 89:
progression for a long time after A
Page 90 and 91:
Table 2. STATUS AT GRAFT Remission
Page 92 and 93:
IL Figura 3 70 SIXTH INTERNATIONAL
Page 94 and 95:
( 5 ) lowed by ABMT than refractory
Page 96 and 97:
74 Figure 4 Low grade lymphoma - pr
Page 98 and 99:
(range 15-55); 68 males and 32 fema
Page 100 and 101:
our experience, this has a seven-ye
Page 102 and 103:
30. Colombat P, Gorin NC, Lemonnier
Page 104 and 105:
82 OVERALL SURUIWL from ABUT (accor
Page 107 and 108:
PROGNOSTIC FACTORS IN ADVANCED STAG
Page 109 and 110:
REFERENCES 1. Chopra R, Mc Millan A
Page 111 and 112:
lished data to attempt to assess th
Page 113 and 114:
1992;10:175-7. 3. McMillan A, Golds
Page 115 and 116:
B. DAILY DAY AGENT DOSE -7 -6 -5 -4
Page 117 and 118:
cohort with HR treated with BEC-2 i
Page 119 and 120:
p R 0 P O R T I 0 N 1 0.9 0.8 0.7 0
Page 121 and 122:
TABLE 3. TOXICITY BEC TAVe TMJ as 2
Page 123 and 124:
ies. 10 Longer blood half-lives hav
Page 125 and 126:
agents have been developed cautious
Page 127 and 128:
Table 1. Radioisotopes for RIT. Pur
Page 129 and 130:
The treatment criterion in this stu
Page 131 and 132:
more than 80% of the cases. Patient
Page 133 and 134:
Disease Free Survival 800 Time •
Page 135:
Session VI: Breast Cancer
Page 138 and 139:
achieved a complete remission survi
Page 140 and 141:
acil, vincristine, prednisone (CMFV
Page 142 and 143:
t: 3 en a in S « J •S •> c ai
Page 144 and 145:
LONG TERM FOLLOW UP OF POOR PROGNOS
Page 146 and 147:
tors both for progression-free surv
Page 148 and 149:
222 INDUCTION PHASE ESTROGEN RECEPT
Page 150 and 151:
THE PHARMACOLOGY OF INTENSIVE CYCLO
Page 152 and 153:
PK VARIABILITY OF CPA/CDDP/BCNU Whe
Page 154 and 155:
5. Groshow LB, Piantadosi S, Santos
Page 157 and 158: - Tn'üTiifi'.m'jii.'yjKJiHtyiwiT T
Page 159 and 160: normal CD34+ progenitor cells
Page 161 and 162: sequence analysis of the human haem
Page 163 and 164: Bielefeld, FRG) or control medium w
Page 165 and 166: 3. Koeffler HP, and Golde DW: Chron
Page 167 and 168: ply infected with supernatants from
Page 169 and 170: controls must be carefully matched
Page 171 and 172: Fig. IB: GPI isozyme analysis of 2
Page 173 and 174: PROCESSING OF STEM CELLS FOR TRANSP
Page 175 and 176: in progress using marker genes to l
Page 177 and 178: Table 1. Factors Affecting Quality
Page 179: Figure 2 .2 A Refractory/Relapsed L
Page 183 and 184: HIGH DOSE CHEMOTHERAPY IN GERM CELL
Page 185 and 186: carboplatin and etoposide with auto
Page 187 and 188: HIGH DOSE THERAPY IN GERM CELL TUMO
Page 189 and 190: Confusing data come out from early
Page 191: Session Mill: Lung Cancer
Page 194 and 195: Of the 14 limited stage patients in
Page 196 and 197: esponses with persistent nodular di
Page 198 and 199: hanced, detection of initial failur
Page 200 and 201: Cellules. Bull Cancer 1987;74:587-5
Page 202 and 203: 30 36 42 48 54 60 66 72 78 84 12 18
Page 204 and 205: Table 2: Toxicity of CBP Regimen fo
Page 206 and 207: TREATMENT OF NONSMALL CELL LUNG CAN
Page 210 and 211: Table 6. Hematological Data of the
Page 212 and 213: ence in survival among the three hi
Page 215: Session IX: Ovarian Cancer
Page 218 and 219: lymph node involvement or parenchym
Page 220 and 221: higher frequencies of neurotoxicity
Page 222 and 223: 12. Ovarian Cancer Meta-Analysis Pr
Page 224 and 225: Table 2. Randomized Trials Employin
Page 226 and 227: BONE MARROW TRANSPLANTATION FOR OVA
Page 228 and 229: 1). Data from the survey was combin
Page 230 and 231: carboplatinum and ifosfamide. The s
Page 233: Session X: Sarcoma
Page 236 and 237: ated doses in a recent Pediatric On
Page 238 and 239: cytokines to reduce hospitalization
Page 240 and 241: TABLE 2 Dose Escalation Schedule Do
Page 243 and 244: CHRONIC MYELOGENOUS LEUKEMIA WITH B
Page 245 and 246: DISCUSSION In this study, the use o
Page 247 and 248: AUTOGRAFTING IN CHRONIC MYELOID LEU
Page 249 and 250: Table 1 Remission Deaths Graft Hema
Page 251 and 252: 16 (800 mg/m2 per day for two conse
Page 253: Session XII: CNS
Page 256 and 257: 1.2 Description of the study The tr
Page 258 and 259:
3. Conclusion In conclusion, treatm
Page 260 and 261:
3. Conclusion Hematological toxicit
Page 263:
Session XIII: Peripheral Stem Cells
Page 266 and 267:
Crouse, 1992). In the present repor
Page 268 and 269:
with no evidence of systemic diseas
Page 270 and 271:
Administration of rhSCF at doses of
Page 272 and 273:
In summary, the ligand for c-kit ha
Page 274 and 275:
AUTOGRAFTING WITH G-CSF-MOBILIZED B
Page 276 and 277:
cells and CD34+ cells observed in t
Page 278 and 279:
6. Brugger W, Bross K, Frisch J, et
Page 280 and 281:
100 -l Collection Efficiency Figure
Page 282 and 283:
MATERIALS AND METHODS PATIENTS. Pat
Page 284 and 285:
None of the patients included in ar
Page 286 and 287:
9. Aurer I, Ribas A, Gale RP. What
Page 288 and 289:
246 o 0.6 b 0.1 B1 Figure 2 p = 0.0
Page 291 and 292:
AUTOLOGOUS BONE MARROW TRANSPLANTAT
Page 293 and 294:
SUMMARY OF THE NON HODGKIN LYMPHOMA
Page 295 and 296:
SUMMARY: AUTOLOGOUS MARROW TRANSPLA
Page 297 and 298:
mor. The obverse of this coin is po
Page 299 and 300:
treated at Memorial Hospital in New
Page 301 and 302:
Contributors and Participants Tause
Page 303 and 304:
Leonard Kalman, Hematology/Oncology
Page 305:
D.R. Sutherland, Oncology Research,
show all

VI Autologous Bone Marrow Transplantation.pdf - Blog Science ...

Create successful ePaper yourself

Delete template?

Save as template?